Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 4/20 | 0.49 |
| ▸ | CHRNA10 | Q9GZZ6 | 4/20 | 0.49 |
| ▸ | CHRNA9 | Q9UGM1 | 4/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401479 | 0.89 | CHRNA7 (0.47) | CHRNA7CHRNA10CHRNA9HTTMAPT | |
| SCHEMBL4401401 | 0.88 | CHRNA7 (0.47) | CHRNA7CHRNA10CHRNA9HTTMEN1 | |
| SCHEMBL9162381 | 0.87 | HTT (0.52) | HTTMEN1MAPTKMT2A | |
| SCHEMBL4403547 | 0.87 | HTT (0.52) | HTTMEN1MAPTKMT2A | |
| SCHEMBL9160448 | 0.87 | HTT (0.52) | HTTMEN1MAPTKMT2A | |
| Iodide SCHEMBL9154731 | 0.85 | HTT (0.50) | HTTMEN1MAPTKMT2A | |
| SCHEMBL9925975 | 0.85 | HTT (0.48) | HTTMEN1MAPTKMT2A | |
| SCHEMBL13231513 | 0.84 | CHRNA7 (0.47) | CHRNA7CHRNA10CHRNA9HTTMEN1 | |
| Water SCHEMBL31247994 | 0.83 | HTT (0.46) | HTTMEN1MAPTKMT2A | |
| SCHEMBL30875788 | 0.83 | HTT (0.46) | HTTMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940774-B2 | Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940774-B2 | Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2015-01-27 | — | — | US | disclosed |
| US-8703803-B2 | Tris-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIV KENTUCKY RES FOUND (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703803-B2 | Tris-quaternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIV KENTUCKY RES FOUND (US) | 2014-04-22 | — | — | US | disclosed |
| US-20140080866-A1 | Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20140080866-A1 | Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2014-03-20 | — | — | US | disclosed |
| US-20130030018-A1 | Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | UNIV KENTUCKY RES FOUND (US) | 2013-01-31 | — | — | US | disclosed |
| US-8299253-B2 | Tris-quarternary ammonium salts and methods for modulating neuronal nicotinic acetylcholine receptors | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20110105556-A1 | TRIS-QUARTERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130030018-A1 | Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA10, CHRNA5, CHRNA2 | CHRNA7 6/4885CHRNA10 1/4885CHRNA9 9/4885 |
| US-20140080866-A1 | Tris-Quaternary Ammonium Salts and Methods for Modulating Neuronal Nicotinic Acetylcholine Receptors | CHRNA4, CHRNA2, CHRNA10 | CHRNA7 7/4885CHRNA10 3/4885CHRNA9 11/4885 |
| US-20110105556-A1 | TRIS-QUARTERNARY AMMONIUM SALTS AND METHODS FOR MODULATING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS | CHRNA5, CHRNA10, CHRNA4 | CHRNA7 4/4885CHRNA10 2/4885CHRNA9 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.